Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker Testing - Episode 9

Key Takeaways for Concurrent Biomarker Testing in NSCLC

,

Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the critical role of both tissue and liquid biopsies, the necessity of rapid time-to-treatment initiation, and the increasing likelihood of liquid biopsies becoming the standard of care for metastatic non-small cell lung cancer patients in the near future.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing
    EP. 2: Concurrent NSCLC Biomarker Testing at Diagnosis
    EP. 3: NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing
    EP. 4: Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer
    EP. 5: Biomarker Testing in Early-Stage NSCLC
    EP. 6: Reflex Testing for Patients with Suspected Lung Cancer
    EP. 7: Challenges of NSCLC Biomarker Testing in Clinical Practice
    EP. 8: Overcoming Barriers to NSCLC Biomarker Testing
    Now Viewing
    EP. 9: Key Takeaways for Concurrent Biomarker Testing in NSCLC
    x